The University of Chicago Header Logo

Connection

David Rubin to Crohn Disease

Back to Details
This is a "connection" page, showing publications David Rubin has written about Crohn Disease.
David Rubin
Connection Strength
29.096
Crohn Disease
  1. Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2026 Mar; 24(3):763-771.
    View in: PubMed
    Score: 0.571
  2. A Guide to the Patient-Centric Use of Vedolizumab for Crohn's Disease. Inflamm Bowel Dis. 2025 Aug 01; 31(8):2269-2285.
    View in: PubMed
    Score: 0.571
  3. Broad Impact of Bowel Urgency in Ulcerative Colitis and Crohn's Disease: US, European, and Japanese Patient and Healthcare Professional Perspectives from the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey. Adv Ther. 2025 Sep; 42(9):4510-4526.
    View in: PubMed
    Score: 0.568
  4. Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study. Inflamm Bowel Dis. 2025 Feb 06; 31(2):432-441.
    View in: PubMed
    Score: 0.552
  5. Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study. J Manag Care Spec Pharm. 2024 Nov; 30(11):1276-1287.
    View in: PubMed
    Score: 0.542
  6. Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2025 Sep; 23(10):1817-1823.
    View in: PubMed
    Score: 0.541
  7. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflamm Bowel Dis. 2024 10 03; 30(10):1776-1787.
    View in: PubMed
    Score: 0.539
  8. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. BMC Gastroenterol. 2024 Sep 17; 24(1):314.
    View in: PubMed
    Score: 0.537
  9. Utility of the Endoscopic Healing Index in Identifying Active Inflammation in Patients with Crohn's Disease: Real World Data from a Tertiary Center. Dig Dis Sci. 2024 Aug; 69(8):2955-2960.
    View in: PubMed
    Score: 0.526
  10. Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease. Dig Dis Sci. 2024 Feb; 69(2):355-359.
    View in: PubMed
    Score: 0.510
  11. Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2024 Jun; 22(6):1336-1338.e2.
    View in: PubMed
    Score: 0.509
  12. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience. Clin Gastroenterol Hepatol. 2023 07; 21(7):1913-1923.e2.
    View in: PubMed
    Score: 0.483
  13. Treat-to-target and sequencing therapies in Crohn's disease. United European Gastroenterol J. 2022 12; 10(10):1121-1128.
    View in: PubMed
    Score: 0.475
  14. Diagnostic and Management Considerations for the IPAA With Crohn's Disease-Like Features. Dis Colon Rectum. 2022 12 01; 65(S1):S77-S84.
    View in: PubMed
    Score: 0.462
  15. Ileal Desmoid Tumor in Ileal Crohn's: Coincidence or Connection? Dig Dis Sci. 2023 03; 68(3):1071-1073.
    View in: PubMed
    Score: 0.459
  16. Upadacitinib Is Safe and Effective for Crohn's Disease: Real-World Data from a Tertiary Center. Dig Dis Sci. 2023 02; 68(2):385-388.
    View in: PubMed
    Score: 0.459
  17. Intestinal Cancer and Dysplasia in Crohn's Disease. Gastroenterol Clin North Am. 2022 06; 51(2):369-379.
    View in: PubMed
    Score: 0.455
  18. Histopathology of Colectomy Specimens Predicts Endoscopic Pouch Phenotype in Patients with Ulcerative Colitis. Dig Dis Sci. 2022 08; 67(8):4020-4031.
    View in: PubMed
    Score: 0.451
  19. International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey. Inflamm Bowel Dis. 2021 11 15; 27(12):1942-1953.
    View in: PubMed
    Score: 0.441
  20. Inclusion of Under-represented Racial and Ethnic Minorities in Randomized Clinical Trials for Inflammatory Bowel Disease. Gastroenterology. 2022 01; 162(1):17-21.
    View in: PubMed
    Score: 0.437
  21. The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies. Inflamm Bowel Dis. 2021 07 27; 27(8):1201-1209.
    View in: PubMed
    Score: 0.432
  22. New targets in inflammatory bowel disease therapy: 2021. Curr Opin Gastroenterol. 2021 07 01; 37(4):357-363.
    View in: PubMed
    Score: 0.430
  23. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United European Gastroenterol J. 2021 06; 9(5):552-560.
    View in: PubMed
    Score: 0.425
  24. Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate. Am J Gastroenterol. 2020 08; 115(8):1298.
    View in: PubMed
    Score: 0.403
  25. Poor Sleep Quality in Crohn's Disease Is Associated With Disease Activity and Risk for Hospitalization or Surgery. Inflamm Bowel Dis. 2020 07 17; 26(8):1251-1259.
    View in: PubMed
    Score: 0.402
  26. Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology. 2020 Jul; 159(1):6-13.e6.
    View in: PubMed
    Score: 0.395
  27. Inpatient Management of Inflammatory Bowel Disease-Related Complications. Clin Gastroenterol Hepatol. 2020 05; 18(6):1346-1355.
    View in: PubMed
    Score: 0.388
  28. Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. Clin Gastroenterol Hepatol. 2020 10; 18(11):2518-2525.e1.
    View in: PubMed
    Score: 0.386
  29. Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. J Crohns Colitis. 2019 Sep 19; 13(9):1158-1162.
    View in: PubMed
    Score: 0.380
  30. Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2018 09 15; 24(10):2135-2141.
    View in: PubMed
    Score: 0.354
  31. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
    View in: PubMed
    Score: 0.349
  32. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
    View in: PubMed
    Score: 0.342
  33. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309.
    View in: PubMed
    Score: 0.338
  34. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. PLoS One. 2017; 12(4):e0175099.
    View in: PubMed
    Score: 0.321
  35. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Manag Care Spec Pharm. 2017 Aug; 23(8):859-867.
    View in: PubMed
    Score: 0.319
  36. The Crohn's and Colitis Foundation of America Survey of Inflammatory Bowel Disease Patient Health Care Access. Inflamm Bowel Dis. 2017 02; 23(2):224-232.
    View in: PubMed
    Score: 0.317
  37. Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis. Curr Med Res Opin. 2017 03; 33(3):529-536.
    View in: PubMed
    Score: 0.315
  38. Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 01; 23(1):152-157.
    View in: PubMed
    Score: 0.315
  39. Safety and Efficacy of Live Measles Vaccine Administered to a Crohn's Disease Patient Receiving Vedolizumab. Am J Gastroenterol. 2016 04; 111(4):577.
    View in: PubMed
    Score: 0.299
  40. Vedolizumab in the treatment of Crohn's disease. Expert Rev Gastroenterol Hepatol. 2016; 10(3):283-90.
    View in: PubMed
    Score: 0.295
  41. Penetrating Disease, Narcotic Use, and Loop Ostomy Are Associated with Ostomy and IBD-related Complications After Ostomy Surgery in Crohn's Disease Patients. J Gastrointest Surg. 2015 Oct; 19(10):1852-61.
    View in: PubMed
    Score: 0.286
  42. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May; 39(10):1143-55.
    View in: PubMed
    Score: 0.260
  43. Describing the clinical phenotypes of Crohn's disease: lessons from the past: commentary on: the broadening conception of regional ileitis. Dig Dis Sci. 2014 Jan; 59(1):6-8.
    View in: PubMed
    Score: 0.256
  44. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83.
    View in: PubMed
    Score: 0.253
  45. Initial experience of a through-the-scope balloon device for ileal intubation in Crohn's disease. Gastrointest Endosc. 2013 Oct; 78(4):669-70.
    View in: PubMed
    Score: 0.251
  46. Chronic pouchitis versus recurrent Crohn's disease: a diagnostic challenge. Dig Dis Sci. 2013 Oct; 58(10):2748-50.
    View in: PubMed
    Score: 0.249
  47. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
    View in: PubMed
    Score: 0.241
  48. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012 Dec; 18(12):2225-31.
    View in: PubMed
    Score: 0.225
  49. Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1026-32.
    View in: PubMed
    Score: 0.224
  50. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflamm Bowel Dis. 2012 May; 18(5):818-25.
    View in: PubMed
    Score: 0.217
  51. A practical, evidence-based guide to the use of adalimumab in Crohn's disease. Curr Med Res Opin. 2011 Sep; 27(9):1803-13.
    View in: PubMed
    Score: 0.216
  52. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
    View in: PubMed
    Score: 0.211
  53. Active Crohn's disease in the small bowel: evaluation by diffusion weighted imaging and quantitative dynamic contrast enhanced MR imaging. J Magn Reson Imaging. 2011 Mar; 33(3):615-24.
    View in: PubMed
    Score: 0.210
  54. Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol. 2008 May 07; 14(17):2662-9.
    View in: PubMed
    Score: 0.173
  55. p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease. Dig Dis Sci. 2008 Feb; 53(2):474-80.
    View in: PubMed
    Score: 0.164
  56. International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials. J Crohns Colitis. 2025 Sep 28; 19(9).
    View in: PubMed
    Score: 0.144
  57. Impact of moderate-to-severe ulcerative colitis and Crohn's disease on sexual activity: United States and European patient perspectives from the communicating needs and features of IBD experiences (CONFIDE) survey. Curr Med Res Opin. 2025 Jun; 41(6):1017-1030.
    View in: PubMed
    Score: 0.142
  58. Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials. Lancet. 2025 Jul 26; 406(10501):358-375.
    View in: PubMed
    Score: 0.142
  59. Development and validation of a novel Endoscopic ulcer Activity Score for Evaluation of Crohn's Disease (EASE-CD) using data from two randomised controlled trials. Lancet Gastroenterol Hepatol. 2025 Aug; 10(8):746-756.
    View in: PubMed
    Score: 0.141
  60. Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis. J Crohns Colitis. 2025 Jun 04; 19(6).
    View in: PubMed
    Score: 0.141
  61. Superior mesenteric vein thrombosis after colectomy in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jun; 2(6):281-5; quiz 1 p following 285.
    View in: PubMed
    Score: 0.141
  62. Association of bile acid diarrhea with symptoms and disease activity in Crohn's disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn's disease. J Crohns Colitis. 2025 May 08; 19(5).
    View in: PubMed
    Score: 0.140
  63. To test or "NOD-2" test: what are the questions? The balanced viewpoint. Inflamm Bowel Dis. 2005 May; 11(5):510-2.
    View in: PubMed
    Score: 0.140
  64. Prevalence and Risk Factors of Spondyloarthritis Symptoms in a US-Based Multicenter Cohort of Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2025 Oct 01; 120(10):2330-2338.
    View in: PubMed
    Score: 0.137
  65. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2025 02; 10(2):138-153.
    View in: PubMed
    Score: 0.136
  66. Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2024 Dec; 69(12):4437-4445.
    View in: PubMed
    Score: 0.136
  67. Noninvasive, microbiome-based diagnosis of inflammatory bowel disease. Nat Med. 2024 Dec; 30(12):3555-3567.
    View in: PubMed
    Score: 0.135
  68. Perianal Fistulizing Crohn's Disease-Associated Anorectal and Fistula Cancers: Systematic Review and Expert Consensus. Clin Gastroenterol Hepatol. 2025 May; 23(6):927-945.e2.
    View in: PubMed
    Score: 0.132
  69. Overview to Challenges in IBD 2024-2029. Inflamm Bowel Dis. 2024 05 23; 30(Suppl 2):S1-S4.
    View in: PubMed
    Score: 0.131
  70. Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Crohn's Disease in US and Europe: Results from the Cross-Sectional CONFIDE Study. Dig Dis Sci. 2024 Jul; 69(7):2333-2344.
    View in: PubMed
    Score: 0.131
  71. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure. Clin Gastroenterol Hepatol. 2024 Oct; 22(10):2096-2106.
    View in: PubMed
    Score: 0.130
  72. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol. 2024 02; 9(2):133-146.
    View in: PubMed
    Score: 0.127
  73. Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease. United European Gastroenterol J. 2023 10; 11(8):797-806.
    View in: PubMed
    Score: 0.125
  74. Crohn's Disease Features in Anastomotic Biopsies from Patients With and Without Crohn's Disease: Diagnostic and Prognostic Value. Mod Pathol. 2023 11; 36(11):100325.
    View in: PubMed
    Score: 0.125
  75. Treatment of Chronic Inflammatory Pouch Conditions With Tofacitinib: A Case Series From 2 Tertiary IBD Centers in the United States. Inflamm Bowel Dis. 2023 09 01; 29(9):1504-1507.
    View in: PubMed
    Score: 0.125
  76. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. Lancet Gastroenterol Hepatol. 2023 09; 8(9):853-859.
    View in: PubMed
    Score: 0.124
  77. Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions. J Crohns Colitis. 2023 Jul 05; 17(7):1066-1078.
    View in: PubMed
    Score: 0.124
  78. Transient Suppression of Bacterial Populations Associated with Gut Health is Critical in Success of Exclusive Enteral Nutrition for Children with Crohn's Disease. J Crohns Colitis. 2023 Jul 05; 17(7):1103-1113.
    View in: PubMed
    Score: 0.124
  79. Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21). BMC Med Res Methodol. 2023 05 25; 23(1):129.
    View in: PubMed
    Score: 0.123
  80. Ultrasonographic Transmural Healing in Crohn's Disease. Am J Gastroenterol. 2023 06 01; 118(6):961-969.
    View in: PubMed
    Score: 0.121
  81. Long-Term Outcomes of the Excluded Rectum in Crohn's Disease: A Multicenter International Study. Inflamm Bowel Dis. 2023 03 01; 29(3):417-422.
    View in: PubMed
    Score: 0.121
  82. Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial. Aliment Pharmacol Ther. 2023 01; 57(2):205-214.
    View in: PubMed
    Score: 0.118
  83. Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. Inflamm Bowel Dis. 2022 09 01; 28(9):1321-1331.
    View in: PubMed
    Score: 0.117
  84. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses. Clin Gastroenterol Hepatol. 2023 08; 21(9):2211-2221.
    View in: PubMed
    Score: 0.116
  85. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
    View in: PubMed
    Score: 0.115
  86. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 05 28; 399(10340):2015-2030.
    View in: PubMed
    Score: 0.114
  87. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022 05 28; 399(10340):2031-2046.
    View in: PubMed
    Score: 0.114
  88. Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. Lancet Gastroenterol Hepatol. 2022 05; 7(5):390-391.
    View in: PubMed
    Score: 0.114
  89. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. Lancet Gastroenterol Hepatol. 2022 07; 7(7):666-678.
    View in: PubMed
    Score: 0.114
  90. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clin Gastroenterol Hepatol. 2022 11; 20(11):2619-2627.e1.
    View in: PubMed
    Score: 0.112
  91. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology. 2022 05; 162(6):1650-1664.e8.
    View in: PubMed
    Score: 0.112
  92. What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented? Gastroenterology. 2022 04; 162(5):1396-1408.
    View in: PubMed
    Score: 0.112
  93. Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95.
    View in: PubMed
    Score: 0.110
  94. Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. Inflamm Bowel Dis. 2021 06 15; 27(7):1008-1016.
    View in: PubMed
    Score: 0.107
  95. Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease: TARGET-IBD. J Clin Gastroenterol. 2022 07 01; 56(6):529-535.
    View in: PubMed
    Score: 0.107
  96. Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis. World J Gastroenterol. 2021 May 28; 27(20):2521-2530.
    View in: PubMed
    Score: 0.107
  97. Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease. J Gastroenterol Hepatol. 2021 Oct; 36(10):2785-2793.
    View in: PubMed
    Score: 0.107
  98. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 04; 160(5):1570-1583.
    View in: PubMed
    Score: 0.105
  99. The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn's Disease. Digestion. 2021; 102(5):767-775.
    View in: PubMed
    Score: 0.105
  100. Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 01 19; 27(2):236-241.
    View in: PubMed
    Score: 0.104
  101. Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. Clin Gastroenterol Hepatol. 2021 10; 19(10):2207-2209.e3.
    View in: PubMed
    Score: 0.102
  102. An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI. Clin Gastroenterol Hepatol. 2021 12; 19(12):2524-2531.
    View in: PubMed
    Score: 0.101
  103. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2021 01; 19(1):104-110.
    View in: PubMed
    Score: 0.098
  104. Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Inflamm Bowel Dis. 2020 01 06; 26(2):304-313.
    View in: PubMed
    Score: 0.097
  105. Capsule Retention in Crohn's Disease: A Meta-analysis. Inflamm Bowel Dis. 2020 01 01; 26(1):33-42.
    View in: PubMed
    Score: 0.097
  106. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation. Inflamm Bowel Dis. 2020 01 01; 26(1):1-10.
    View in: PubMed
    Score: 0.097
  107. Renin-angiotensin system promotes colonic inflammation by inducing TH17 activation via JAK2/STAT pathway. Am J Physiol Gastrointest Liver Physiol. 2019 06 01; 316(6):G774-G784.
    View in: PubMed
    Score: 0.092
  108. Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275.
    View in: PubMed
    Score: 0.091
  109. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 01; 13(1):50-57.
    View in: PubMed
    Score: 0.090
  110. A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Aliment Pharmacol Ther. 2018 11; 48(9):933-940.
    View in: PubMed
    Score: 0.088
  111. Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: a prospective study. Gastrointest Endosc. 2018 12; 88(6):947-955.e2.
    View in: PubMed
    Score: 0.088
  112. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis. 2018 Apr 27; 12(5):621-626.
    View in: PubMed
    Score: 0.086
  113. Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology. 2018 07; 155(1):76-87.
    View in: PubMed
    Score: 0.086
  114. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
    View in: PubMed
    Score: 0.085
  115. Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis. 2017 Apr 01; 11(4):412-424.
    View in: PubMed
    Score: 0.080
  116. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Dig Dis Sci. 2017 04; 62(4):833-842.
    View in: PubMed
    Score: 0.080
  117. Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis. Dig Dis Sci. 2016 10; 61(10):2972-2976.
    View in: PubMed
    Score: 0.077
  118. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80.
    View in: PubMed
    Score: 0.076
  119. Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel. Inflamm Bowel Dis. 2016 06; 22(6):1418-24.
    View in: PubMed
    Score: 0.076
  120. Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. Inflamm Bowel Dis. 2016 May; 22(5):1027-31.
    View in: PubMed
    Score: 0.075
  121. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7.
    View in: PubMed
    Score: 0.074
  122. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. Curr Gastroenterol Rep. 2016 Jan; 18(1):5.
    View in: PubMed
    Score: 0.073
  123. Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States. Am J Gastroenterol. 2016 Jan; 111(1):15-23.
    View in: PubMed
    Score: 0.071
  124. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1919-25.
    View in: PubMed
    Score: 0.070
  125. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
    View in: PubMed
    Score: 0.067
  126. Clinical presentation and disease course of inflammatory bowel disease differs by race in a large tertiary care hospital. Dig Dis Sci. 2014 Sep; 59(9):2228-35.
    View in: PubMed
    Score: 0.065
  127. Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis. 2013 Oct; 19(11):2440-3.
    View in: PubMed
    Score: 0.063
  128. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis. 2013 May; 19(6):1112-22.
    View in: PubMed
    Score: 0.061
  129. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb; 19(2):363-9.
    View in: PubMed
    Score: 0.060
  130. Genetic testing for inflammatory bowel disease: focus group analysis of patients and family members. Genet Test Mol Biomarkers. 2009 Aug; 13(4):495-503.
    View in: PubMed
    Score: 0.047
  131. Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study. Acad Radiol. 2009 Oct; 16(10):1223-30.
    View in: PubMed
    Score: 0.047
  132. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008 Dec; 103(12):3132-41.
    View in: PubMed
    Score: 0.044
  133. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest. 2008 Oct; 88(10):1110-20.
    View in: PubMed
    Score: 0.044
  134. The complexity and challenges of genetic counseling and testing for inflammatory bowel disease. J Genet Couns. 2006 Dec; 15(6):465-76.
    View in: PubMed
    Score: 0.039
  135. Histopathologic Evaluation and Single-cell Spatial Transcriptomics of the Colon Reveal Cellular and Molecular Abnormalities Linked to J-Pouch Failure in Patients With Inflammatory Bowel Disease. Cell Mol Gastroenterol Hepatol. 2025; 19(10):101563.
    View in: PubMed
    Score: 0.035
  136. Fever and right upper quadrant pain in a pregnant woman at 30 weeks' gestation. Nat Clin Pract Gastroenterol Hepatol. 2004 Dec; 1(2):113-6; quiz 1 p following 116.
    View in: PubMed
    Score: 0.034
  137. Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD. J Crohns Colitis. 2024 Apr 23; 18(4):548-559.
    View in: PubMed
    Score: 0.033
  138. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365.
    View in: PubMed
    Score: 0.025
  139. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
    View in: PubMed
    Score: 0.025
  140. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
    View in: PubMed
    Score: 0.023
  141. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2017 Oct 01; 11(10):1180-1199.
    View in: PubMed
    Score: 0.021
  142. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Dec; 10(12):1385-1394.
    View in: PubMed
    Score: 0.019
  143. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011 Jul; 60(7):937-43.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.